• The current market size for next-generation sequencing-based (NSG) single-cell RNA sequencing is $1.7 billion, and it is projected to reach $4.2 billion by 2024.

• The single-cell RNA sequencing market is projected to grow at a CAGR of 20.0% between 2019 and 2024. The North American region is the current market leader and is projected to remain dominant in the period under review.

• According to a recent report, expression profiling analysis accounts for the largest share of the NGS-based RNA sequencing market due to the increasing prevalence of multiple sclerosis, metabolic disorders, and other diseases.

•  Illumina, a US-based single-cell RNA sequencing company, currently dominates the market. It offers both single-cell sequencing products and services. The company has been able to maintain its lead in this market by investing heavily in R&D and fostering strategic partnerships with other companies.

• Other notable players in this market, as reported by MarketWatch, include Thermo Fisher Scientific Inc., Pacific Biosciences of California, Inc., Qiagen N.V., F. Hoffmann-La Roche AG, and Agilent Technologies, Inc.

Summation Of The Availability Of Information Relevant To The Goals

• In our initial hour of research, we were able to provide the current and projected market size for the single-cell RNA sequencing market, as well as its projected growth rate.

• We were also able to identify the top players in this market and provide brief information on the market dynamics as a whole.